DEF: Viking Therapeutics Sets 2026 Annual Meeting Agenda

Viking Therapeutics, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors, ratify auditors, and approve executive compensation.

Summary

• The Annual Meeting of Stockholders will be held virtually on Tuesday, May 19, 2026, at 8:00 a.m. Pacific Time.
• Stockholders will vote on the election of J. Matthew Singleton and S. Kathryn Rouan, Ph.D. as Class II directors to serve until the 2029 Annual Meeting.
• The ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is also on the agenda.
• An advisory vote to approve the compensation of named executive officers will be conducted.
• The record date for voting is March 20, 2026, with 115,893,943 shares of common stock outstanding and entitled to vote.
• The company achieved a Total Shareholder Return (TSR) of 525% in 2025, significantly exceeding the industry return of 25%.
• Net Loss for 2025 increased to $359.6 million, compared to $110.0 million in 2024 and $85.9 million in 2023.
• The Chief Operating Officer, Marianne Mancini, will retire effective April 30, 2026.
• Executive compensation for 2025 included a bonus attainment rate of 92.5% based on corporate and stretch goals.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the exceptional TSR and high achievement of corporate and stretch goals, indicating strong operational performance and investor confidence despite increasing net losses typical for a development-stage biotech.

Positives

• The company achieved an exceptional Total Shareholder Return (TSR) of 525% in 2025, vastly outperforming the industry average of 25%.
• Corporate goals for 2025 were achieved at a rate of 79.5%, with an additional 13.0% of stretch goals satisfied, totaling 92.5% attainment.
• Successful initiation, enrollment, and conclusion of clinical trials, leading to positive data readouts, were key operational achievements.
• A long-term supply of active pharmaceutical ingredients and fill-finish supply with backup was secured.
• Significant progress was made in developing the commercial strategy and staffing plan.
• Stockholders approved the 2024 say-on-pay proposal with 67% of votes in favor, indicating general support for executive compensation practices.

Negatives

• Net Loss significantly increased to $359.6 million in 2025, up from $110.0 million in 2024 and $85.9 million in 2023.
• Chief Operating Officer Marianne Mancini is retiring effective April 30, 2026, which will necessitate a transition in a key leadership role.
• The CEO pay ratio for 2025 was 49 to 1, which may draw scrutiny from some stakeholder groups.

Risks

• The company operates in a highly competitive market for talented individuals in the life sciences industry, posing challenges for executive recruitment and retention.
• There is a potential for compensation policies and practices to encourage excessive risk-taking, although the Compensation Committee believes its balanced approach mitigates this.
• As a research and development company without revenue, the company's annual incentive objectives are tied to clinical, program, and regulatory metrics rather than financial goals, which may not directly reflect immediate financial performance.
• General risks include those pertaining to financial, accounting, tax matters, privacy, cybersecurity, competition, legislative and regulatory developments, technology and facilities obsolescence, business continuity, and natural and man-made disasters.

Future Outlook

The company's executive compensation program is designed to incentivize long-term value creation by aligning executive interests with growth drivers and strategic objectives, with a significant portion of pay being at-risk and performance-based. Future compensation decisions will consider stockholder feedback from the annual say-on-pay vote.

Management Comments

• Our Board believes our compensation program should align executive interests with the drivers of growth and stockholder returns, and support achievement of our key business mission, goals and objectives.
• Our executive officer compensation program is designed to reward achievement of the specific strategic goals that we believe will advance our business strategy and create long-term value for our stockholders.
• We believe our balanced approach to performance measurement and pay delivery works to avoid misaligned incentives for individuals to undertake excessive or inappropriate risk.

Industry Context

StockSavvy.ai notes that Viking Therapeutics' impressive 525% TSR in 2025, significantly outpacing the industry's 25% return, highlights strong operational execution in a competitive biotechnology landscape. However, the increasing net losses, common for R&D-focused biotechs, underscore the capital-intensive nature of drug development. The company's reliance on clinical and regulatory milestones for executive incentives, rather than financial metrics, is a standard practice in the pre-revenue biotech sector, aligning compensation with pipeline progress, similar to peers like Akero Therapeutics or Madrigal Pharmaceuticals.

Comparison to Industry Standards

• Viking Therapeutics' 2025 Total Shareholder Return (TSR) of 525% significantly outperformed the industry average of 25%, indicating strong market confidence and operational success relative to its peers.
• The company's executive compensation structure, with a significant portion tied to performance-based equity awards and annual cash incentives linked to clinical and regulatory milestones, is consistent with industry standards for pre-commercial biotechnology companies. This approach is similar to that observed in companies like Akero Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc., which also focus on pipeline development.
• The increasing net losses, reaching $359.6 million in 2025, are typical for a research and development-stage biotechnology company heavily investing in clinical trials and pipeline expansion, comparable to the financial profiles of other development-stage biopharmaceutical companies in the peer group such as BridgeBio Pharma, Inc. or Dyne Therapeutics, Inc.
• The CEO pay ratio of 49 to 1, while seemingly high, is within the range observed in the biotechnology sector, where executive compensation often includes substantial equity components reflecting long-term value creation potential rather than immediate profitability.

Management Changes

Corporate Governance

Related Party Transactions

• No transactions exceeding $120,000 with related persons were disclosed, other than director and executive officer compensation arrangements.

Stakeholder Impact

• Shareholders: Direct impact through voting on directors, auditor ratification, and executive compensation. Significant positive impact from 525% TSR in 2025. New stock ownership policy aims to align executive and director interests with long-term shareholder value.
• Employees: Eligible for 401(k) plan. Executive compensation structure aims to motivate and retain key talent. Option to take up to 50% of 2025 bonus in fully-vested stock options.
• Customers/Patients: Indirectly impacted by the company's focus on advancing clinical trials and developing new pipeline products, which could lead to new therapies.
• Management: Compensation tied to corporate performance and milestone achievement. Retirement of COO Marianne Mancini will require a transition.

Next Steps

• Elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D. as Class II directors at the 2026 Annual Meeting.
• Ratify CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026.
• Conduct an advisory vote on the compensation of named executive officers at the 2026 Annual Meeting.
• Marianne Mancini will retire as Chief Operating Officer effective April 30, 2026.
• The Board and Compensation Committee will review the results of the say-on-pay vote and consider them in future executive compensation decisions.
• Stockholders may submit proposals for the 2027 Annual Meeting by December 2, 2026 (for inclusion in proxy materials) or between January 19, 2027, and February 18, 2027 (not for proxy materials).
• The next say-on-pay vote will be held at the 2027 Annual Meeting of Stockholders.

Key Dates

Recommendation

The company demonstrated exceptional Total Shareholder Return (TSR) of 525% in 2025, vastly outperforming the industry. This indicates strong operational momentum and investor confidence in its pipeline and strategic execution, despite increasing net losses which are typical for a development-stage biotech. The high achievement of corporate and stretch goals further reinforces a positive outlook for future milestones. While the COO's retirement is a change, the overall strategic direction and performance metrics suggest continued growth potential.

Keywords

Viking Therapeutics, DEF 14A, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Shareholder Vote, Biotechnology, Clinical Trials, Drug Development, SEC Filing, VTX